Improving Medicines for Patients

Chiral Switching"

Recent News

Deuterium switcheroo breathes life into old drugs Chemical & Engineering News cover story (Jul 4, 2016)

Deuterated drugs draw heavier backing Nature Reviews Drug Discovery (Apr 1, 2016)

DeuteRx Presents DRX-065 for the Treatment of NASH at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (Nov 11, 2015)

DeuteRx Announces $2.8 Million of Seed Financing to Support Advancement of DRX-065 for the Treatment of Adrenoleukodystrophy (ALD) (Sep 30, 2015)

Drugs that live long will prosper - A simple change to some pharmaceuticals might boost their efficacy, and make a few firms a packet along the way, The Economist (Sep 5, 2015)

DeuteRx Demonstrates Novel Approach to Chiral Switching for Racemic Marketed Drugs and Drug Candidates using DECS Platform - Results with Thalidomide Analogs Published in PNAS (Mar 2015)

Success Story

DeuteRx, LLC was spun-out from and funded by former shareholders of Deuteria Pharmaceuticals, Inc. in December 2012. The success of both companies is based on 'Deuterium-Enabled Chiral Switching' (DECS), a revolutionary strategy to improve the properties of racemic small molecule marketed drugs and drug candidates. Deuteria was sold to a major biopharmaceutical company in December 2012, <2 years after incorporation.

Commercial Value

DeuteRx has pioneered a novel approach to the successful and profitable strategy of ‘chiral switching’. Today, numerous drugs are still developed and marketed with racemic active ingredients because the enantiomers are chemically unstable and rapidly interconvert in vivo. Representative marketed drugs include Actos®, Aricept®, Contrave®, and Revlimid®. Replacing the exchangable hydrogen at the chiral center with deuterium can enable stabilization and development of the single, preferred enantiomer to create an improved NCE with new composition of matter patent protection.